Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maha Hussain

Showing results (131-140 of 213) with videos related to

Pageof 22
Sort By:
The Journal of Urology|May 14, 2013
Castration-resistant prostate cancer: AUA GuidelineMichael S Cookson, Bruce J Roth, Philipp Dahm, et al.
Prostate Cancer and Prostatic Diseases|February 29, 2024
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronelPrimo N Lara, Edward Mayerson, Erik Gertz, et al.
Prostate Cancer and Prostatic Diseases|September 14, 2021
Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trialsBertrand F Tombal, Stephen J Freedland, Andrew J Armstrong, et al.
Clinical Genitourinary Cancer|April 18, 2020
Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate CancerDavid C Smith, Stephanie Daignault-Newton, Petros Grivas, et al.
Plos One|March 2, 2016
ADAM15 Is Functionally Associated with the Metastatic Progression of Human Bladder CancerGuadalupe Lorenzatti Hiles, Amanda Bucheit, John R Rubin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916Maha Hussain, Bryan Goldman, Cathy Tangen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2018
Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate CancerAlicia K Morgans, Yu-Hui Chen, Christopher J Sweeney, et al.
The Journal of Urology|April 28, 2015
Circulating Tumor Cells as Potential Biomarkers in Bladder CancerAjjai Alva, Terence Friedlander, Melanie Clark, et al.
JCI Insight|March 31, 2026
AURKA inhibitor VIC-1911 induces mitotic defects and functional BRCAness, sensitizing prostate cancer to PARP inhibitionGalina Gritsina, Sandip Kumar Rath, Hongshun Shi, et al.
European Urology|April 22, 2023
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) BluesNick Beije, Wassim Abida, Emmanuel S Antonarakis, et al.
Pageof 22

Showing results (131-140 of 213) with videos related to

Sort By:
Pageof 22
The Journal of Urology|May 14, 2013
Castration-resistant prostate cancer: AUA GuidelineMichael S Cookson, Bruce J Roth, Philipp Dahm, et al.
Prostate Cancer and Prostatic Diseases|February 29, 2024
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronelPrimo N Lara, Edward Mayerson, Erik Gertz, et al.
Prostate Cancer and Prostatic Diseases|September 14, 2021
Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trialsBertrand F Tombal, Stephen J Freedland, Andrew J Armstrong, et al.
Clinical Genitourinary Cancer|April 18, 2020
Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate CancerDavid C Smith, Stephanie Daignault-Newton, Petros Grivas, et al.
Plos One|March 2, 2016
ADAM15 Is Functionally Associated with the Metastatic Progression of Human Bladder CancerGuadalupe Lorenzatti Hiles, Amanda Bucheit, John R Rubin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916Maha Hussain, Bryan Goldman, Cathy Tangen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2018
Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate CancerAlicia K Morgans, Yu-Hui Chen, Christopher J Sweeney, et al.
The Journal of Urology|April 28, 2015
Circulating Tumor Cells as Potential Biomarkers in Bladder CancerAjjai Alva, Terence Friedlander, Melanie Clark, et al.
JCI Insight|March 31, 2026
AURKA inhibitor VIC-1911 induces mitotic defects and functional BRCAness, sensitizing prostate cancer to PARP inhibitionGalina Gritsina, Sandip Kumar Rath, Hongshun Shi, et al.
European Urology|April 22, 2023
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) BluesNick Beije, Wassim Abida, Emmanuel S Antonarakis, et al.
Pageof 22